Amdocs Q4 EPS to beat forecast of 38 cents

October 27, 2005 23:14
1 minute read.


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analysis from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


Amdocs's preliminary figures show that fourth-quarter diluted earnings per share beat its forecast of 38 cents, having risen from 30 cents a year earlier.

The billing software company said Thursday in the three months ending on September 30 revenue rose in line with guidance to $573 million from $452.5m. in the same period in 2004, but the EPS figures excluded acquisition-related costs and other charges. The company didn't provide full net-profit figures for the quarter.

In July, Amdocs bought the cable broadband and satellite TV customer care and billing units of DST Systems Group for $238m., and in August it bought Chinese company Longshine Information Technology for approximately $30m.

Analyst expectations for fourth-quarter EPS range from 37 cents to 39 cents and for revenue they range from $572.93m. to $575.2m., as compiled by Thomson Financial Network.

Amdocs Management chief executive Dov Baharav said the company achieved several milestones in the fourth quarter and it had some "significant" wins that would lead to growth.

"Overall, our existing business is strong and we are confident that with our combination of products and services we provide a superior and low-risk value proposition to our customers," he said.

Following the disclosure of the preliminary figures, shares were up 2.1 percent at $26.02 in early afternoon trading on the New York Stock Exchange. Amdocs is due to release its full earnings report November 9.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection


Cookie Settings